|
WO2021063367A1
|
|
Resmetirom crystal form and preparation method therefor and use thereof
|
|
WO2021077994A1
|
|
Crystal form of hypoxia-inducible factor-prolyl hydroxylase inhibitor
|
|
WO2020177705A1
|
|
Filgotinib maleate crystal form csi, preparation method therefor and use thereof
|
|
WO2020177645A1
|
|
Upadacitinib crystal form and preparation method therefor and use thereof
|
|
WO2020151672A1
|
|
Dapagliflozin crystal form, preparation therefor, and use thereof
|
|
WO2020063939A1
|
|
Crystal form of upadacitinib and preparation method and use thereof
|
|
WO2020057622A1
|
|
Cabozantinib malate crystal form, preparation method therefor and use thereof
|
|
CA3104026A1
|
|
Crystal form of arn-509, preparation method therefor and use thereof
|
|
WO2019205812A1
|
|
New crystal form of acalabrutinib, preparation method therefor and use thereof
|
|
WO2019149262A1
|
|
Crystal form of sb-939, preparation method and use thereof
|
|
KR20200103781A
|
|
Crystalline form of balbenazine tosylate and its preparation method and use
|
|
WO2019105388A1
|
|
Crystal form of a3 adenosine receptor agonist drug, and preparation method therefor and use thereof
|
|
WO2019105359A1
|
|
Crystal form of acalabrutinib, preparation method therefor and application thereof
|
|
KR20200106511A
|
|
New crystal form of acalabrutinib and its preparation method and use
|
|
CN111225671A
|
|
Crystal of selective progesterone receptor regulator and preparation method thereof
|
|
WO2019114394A1
|
|
Crystal form of eb-1020, preparation method therefor and uses thereof
|
|
WO2019042383A1
|
|
Crystalline forms of galunisertib, preparation method therefor, and use thereof
|
|
WO2019137027A1
|
|
Crystal form of galunisertib and preparation method and use thereof
|
|
WO2019105082A1
|
|
Crystal form of galunisertib and preparation method therefor and use thereof
|
|
CN110944982A
|
|
Crystal form of ozapimod hydrochloride and preparation method thereof
|
